



Figure caption: Histology of affected joints 30 days after withdrawal of therapy. Paws were collected, fixed and stained with H&E and scored as aforementioned (see page 1747).

Editor

Tore K Kvien

Associate Editors

Francis Berenbaum
Hans Bijlsma
David Pisetsky
Dimitrios Boumpas
Gerd Burmester
Mary Crow
Iain McInnes

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 7383 6250
F: +44 (0)20 7383 6668
E: ard@bmj.com
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)
Impact Factor: 8.727

Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2012 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior permission. ARD is published by BMJ Publishing Group Ltd typeset by Techset and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431. POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.



Receive regular table of contents by email.
Register using this QR code.

Editorial

- 1593** NSAIDs and radiographic progression in ankylosing spondylitis: Bagging big game with small arms?
N Haroon, T-H Kim, R D Inman

Viewpoint

- 1596** The 2010 ACR/EULAR criteria for rheumatoid arthritis: do they affect the classification or diagnosis of rheumatoid arthritis?
A H M van der Helm-van Mil, T W J Huizinga

Recommendation

- 1599** Guidelines for the genetic diagnosis of hereditary recurrent fevers
Y Shinar, L Obici, I Aksentijevich, B Bennetts, F Austrup, I Ceccherini, J M Costa, A De Leener, M Gattorno, U Kania, I Kone-Paut, S Lezer, A Livneh, I Moix, R Nishikomori, S Ozen, L Phylactou, L Risom, D Rowczenio, T Sarkisian, M E van Gijn, M Witsch-Baumgartner, M Morris, H M Hoffman, I Toutou

Review

- 1606** How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear?
A M Kerola, M J Kauppi, T Kerola, T V M Nieminen

Clinical and epidemiological research

- 1616** Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort
D Poddubnyy, M Rudwaleit, H Haibel, J Listing, E Märker-Hermann, H Zeidler, J Braun, J Sieper
- 1623** Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis
F Kroon, R Landewé, M Dougados, D van der Heijde
- 1630** Clinical evaluation of the efficacy of the P2X₇ purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine
E C Keystone, M M Wang, M Layton, S Hollis, I B McInnes, on behalf of the D1520C00001 Study Team
- 1636** Do worsening scleroderma capillaroscopic patterns predict future severe organ involvement? a pilot study
V Smith, S Decuman, A Sulli, C Bonroy, Y Piette, E Descheppe, F de Keyser, M Cutolo
- 1640** Relationship between area-level socio-economic deprivation and autoantibody status in patients with rheumatoid arthritis: multicentre cross-sectional study
S L Mackie, J C Taylor, S Twigg, S G Martin, S Steer, J Worthington, A Barton, A G Wilson, L Hocking, A Young, P Emery, J H Barrett, A W Morgan
- 1646** Positive association between *STAT4* polymorphisms and polymyositis/dermatomyositis in a Japanese population
T Sugura, Y Kawaguchi, K Goto, Y Hayashi, R Tsuburaya, T Furiya, T Gono, I Nishino, H Yamanaka

- 1651** Genetic variants in *IL15* associate with progression of joint destruction in rheumatoid arthritis: a multicohort study
R Knevel, A Krabben, E Brouwer, M D Posthumus, A G Wilson, E Lindqvist, T Saxne, D de Rooy, N Daha, M P M van der Linden, G Stoecken, L van Toorn, B Koelman, R Tsunaka, A Zhemakova, J J Houwing-Duistermaat, R Toes, T W J Huizinga, A van der Helm-van Mil

- 1658** Realignment treatment for medial tibiofemoral osteoarthritis: randomised trial
D Hunter, K D Gross, P McCree, L Li, K Hirko, W F Harvey

- 1666** Antibodies binding to citrullinated telopeptides of type I and type II collagens and to mutated citrullinated vimentin synergistically predict the development of seropositive rheumatoid arthritis
M-K Koivula, M Heliövaara, H Rissanen, T Palosuo, P Knekt, H Immonen, J Risteli

- 1671** Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160
J S Smolen, J Kay, R B M Landewé, E L Matteson, N Gaylis, J Wollenhaupt, F T Murphy, Y Zhou, E C Hsia, Mitie K Doyle

- 1680** Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists
A Finckh, B Möller, J Dudler, U A Walker, D Kyburz, C Gabay, on behalf of the physicians of the Swiss Clinical Quality Management for Rheumatoid Arthritis

- 1686** Predicting longitudinal trajectory of bone mineral density in paediatric systemic lupus erythematosus patients
L S H Lim, S M Benseler, P N Tyrrell, E Harvey, D Herbert, M Charron, E D Silverman

- 1692** Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study
M F Bakker, G Cavet, J W G Jacobs, J W J Bijlsma, D J Haney, Y Shen, L K Hesterberg, D R Smith, M Centola, J A G van Roon, F P J G Lafeyre, P M J Welsing

MORE CONTENTS ►



This article has been chosen by the Editor to be of special interest or importance and is freely available online.



Articles carrying the Unlocked Logo are freely available online under the BMJ Journals unlocked scheme. See <http://ard.bmj.com/info/unlocked.dtd>



This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

www.publicationethics.org.uk



1698 The association between erosive hand osteoarthritis and subchondral bone attrition of the knee: the Framingham Osteoarthritis Study
I K Haugen, D T Felson, M Englund, K Wang, P Aliabadi, A Guermazi, F W Roemer, T Neogi

1702 Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions
P Studenic, J S Smolen, D Aletaha

Basic and translational research

1706 TLR9 agonist CpG enhances protective nasal HSP60 peptide vaccine efficacy in experimental autoimmune arthritis
E Zonneveld-Huijssoon, F van Wijk, S Roord, E Delemarre, J Meerding, W de Jager, M Klein, E Raz, S Albani, W Kuis, M Boes, B J Prakken

1716 Identification of microRNA-221/222 and microRNA-323-3p association with rheumatoid arthritis via predictions using the human tumour necrosis factor transgenic mouse model
I Pandis, C Ospelt, N Karagianni, M C Denis, M Reczko, C Camps, A G Hatzigeorgiou, J Ragoussis, S Gay, G Kollias

1724 Adiponectin isoforms: a potential therapeutic target in rheumatoid arthritis?
K W Frommer, A Schäffler, C Büchler, J Steinmeyer, M Rickert, S Rehart, F Brentano, S Gay, U Müller-Ladner, E Neumann

1733 Mesenchymal stem cells are conditionally therapeutic in preclinical models of rheumatoid arthritis
A Papadopoulou, M Yangou, E Athanasiou, N Zogas, P Kaloyannidis, I Batsis, A Fassas, A Anagnostopoulos, E Yannaki

1741 Incomplete response of inflammatory arthritis to TNF α blockade is associated with the Th17 pathway
S Alzabin, S M Abraham, T E Taher, A Palfreeman, D Hull, K McNamee, A Jawad, E Pathan, A Kinderlerer, P C Taylor, R Williams, R Mageed

Letters

1749 B cell or T cell-dominant recurrence after rituximab therapy in patients with SLE
S Iwata, K Saito, M Tokunaga, Y Tanaka

1751 Rituximab versus oral cyclophosphamide for treatment of relapses of proliferative lupus nephritis: a clinical observational study
G Moroni, B Gallelli, R A Sinico, G Romano, L Sinigaglia, P Messa

1753 Studying associations between variants in *TRAF1-C5* and *TNFAIP3-OLIG3* and the progression of joint destruction in rheumatoid arthritis in multiple cohorts
R Knevel, D P de Rooy, P K Gregersen, E Lindqvist, A G Wilson, G Gröndal, A Zhenakova, J A van Nies, R E Toes, R Tsonaka, J J Houwing-Duistermaat, K Steinsson, T W Huizinga, T Saxne, A H van der Helm-van Mil

1755 Relapse patterns in IgG4-related disease
M Yamamoto, H Takahashi, K Ishigami, H Yajima, Y Shimizu, T Tabeya, M Matsui, C Suzuki, Y Naishiro, K Imai, Y Shinomura

Miscellaneous

1756 Corrections